TY - JOUR T1 - Dose-Dependent EEG Effects of Zolpidem Provide Evidence for GABA<sub>A</sub> Receptor Subtype Selectivity in Vivo JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 1251 LP - 1257 DO - 10.1124/jpet.102.044859 VL - 304 IS - 3 AU - S. A. G. Visser AU - F. L. C. Wolters AU - P. H. van der Graaf AU - L. A. Peletier AU - M. Danhof Y1 - 2003/03/01 UR - http://jpet.aspetjournals.org/content/304/3/1251.abstract N2 - Zolpidem is a nonbenzodiazepine GABAA receptor modulator that binds in vitro with high affinity to GABAA receptors expressing α1 subunits but with relatively low affinity to receptors expressing α2, α3, and α5 subunits. In the present study, it was investigated whether this subtype selectivity could be detected and quantified in vivo. Three doses (1.25, 5, and 25 mg) of zolpidem were administered to rats in an intravenous infusion over 5 min. The time course of the plasma concentrations was determined in conjunction with the change in the β-frequency range of the EEG as pharmacodynamic endpoint. The concentration-effect relationship of the three doses showed a dose-dependent maximum effect and a dose-dependent potency. The data were analyzed for one- or two-site binding using two pharmacodynamic models based on 1) the descriptive model and 2) a novel mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model for GABAAreceptor modulators that aims to separates drug- and system-specific properties, thereby allowing the estimation of in vivo affinity and efficacy. The application of two-site models significantly improved the fits compared with one-site models. Furthermore, in contrast to the descriptive model, the mechanism-based PK/PD model yielded dose-independent estimates for affinity (97 ± 40 and 33,100 ± 14,800 ng · ml−1). In conclusion, the mechanism-based PK/PD model is able to describe and explain the observed dose-dependent EEG effects of zolpidem and suggests the subtype selectivity of zolpidem in vivo. The American Society for Pharmacology and Experimental Therapeutics ER -